SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VICL (Vical Labs)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Scott H. Davis who wrote (1052)7/4/1999 10:16:00 PM
From: William Strop  Read Replies (1) of 1972
 
Scott,

Here is the start of the Malaria Phase I results press release..

**********

VICAL AND U.S. NAVY DEMONSTRATE DNA VACCINE TECHNOLOGY
IN MAN
Trial Results for Novel Malaria Vaccine Published in Science

WASHINGTON, D.C.—October 15, 1998—In the October 16, 1998, issue of
Science, researchers report the first demonstration of safety and "killer" cytotoxic T lymphocyte (CTL) immune responses in healthy human volunteers of a novel "naked" DNA vaccine technology. Scientists from the Naval Medical Research Center (NMRC), Vical Incorporated (Nasdaq:VICL), the U.S. Army Medical Research Institute of Infectious Diseases, and Pasteur Mérieux Connaught (Rhône-Poulenc Group) report that the majority of 20 subjects immunized with a potential malaria DNA vaccine developed CTL responses, and that the responses were dose-related.

************

I have a question... Does overbought mean anything in a market like we have seen over the past several years???

Bill
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News